COHERUS ONCOLOGY INC (CHRS)
Health Care · NASDAQ
Coherus Oncology is a commercial-stage immuno-oncology company developing next-generation PD-1 inhibitors and checkpoint inhibitors for difficult-to-treat cancers including nasopharyngeal carcinoma, hepatocellular carcinoma, and head & neck squamous cell carcinoma.
What COHERUS ONCOLOGY INC does
Coherus Oncology is a fully integrated commercial-stage immuno-oncology company with an FDA-approved PD-1 inhibitor, LOQTORZI (toripalimab-tpzi), for nasopharyngeal carcinoma in the United States. The company has a pipeline of two mid-stage clinical candidates—casdozokitug (IL-27 antagonist) and tagmokitug (CCR8-targeting antibody)—designed to overcome immune resistance in cancer and intended to be developed in combination with LOQTORZI and partner agents. Coherus executes a coordinated strategy to develop new indications for LOQTORZI while advancing its pipeline through internal development and strategic partnerships globally.
Themes: ["immuno-oncology / checkpoint inhibitors","PD-1 inhibitors","nasopharyngeal carcinoma","hepatocellular carcinoma","head & neck squamous cell carcinoma","immune resistance / tumor microenvironment","cancer immunotherapy combinations"]
Fundamentals
- Price$1.63 as of 2026-07-09 close
- Market cap$255M as of 2026-07-10
- 1-year return+87.8% as of 2026-07-09 close
- P/E1.37 as of 2026-07-10
- Net margin+397.3% as of 2026-07-10
- Gross margin+68.1% as of 2026-07-10
- ROE+214.6% as of 2026-07-10
- Debt / equity0.66 as of 2026-07-10
- Revenue growth (YoY)-76.3% as of 2026-07-10
- Beta0.93 as of 2026-07-10
Key risks (from latest filing)
[]
Competitors & peers
- Merck (Keytruda, PD-1 inhibitor)
- Bristol Myers Squibb (Opdivo, PD-1 inhibitor)
- Roche/Genentech (Tecentriq, PD-L1 inhibitor)
- AstraZeneca (Imfinzi, PD-L1 inhibitor)
- Regeneron (Libtayo, PD-1 inhibitor)
- Junshi Biosciences (toripalimab, co-developer)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.